Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
作者： Anthony B El-Khoueiry , Bruno Sangro , Thomas Yau , Todd S Crocenzi , Masatoshi Kudo
DOI: 10.1016/S0140-6736(17)31046-2
关键词:
摘要: Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …
pubmed.cn
elsevier.com
hku.hk参考文章(26)
Theresa L. Whiteside, Sandra Demaria, Maria E. Rodriguez-Ruiz, Hassane M. Zarour, Ignacio Melero, Emerging Opportunities and Challenges in Cancer Immunotherapy. Clinical Cancer Research. ,vol. 22, pp. 1845- 1855 ,(2016) , 10.1158/1078-0432.CCR-16-0049
A. Williams, EuroQol : a new facility for the measurement of health-related quality of life Health Policy. ,vol. 16, pp. 199- 208 ,(1990)
Robert L Ferris, George Blumenschein Jr, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara C Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J Geese, Justin Kopit, James W Shaw, Maura L Gillison, None, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck The New England Journal of Medicine. ,vol. 375, pp. 1856- 1867 ,(2016) , 10.1056/NEJMOA1602252
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Masatoshi Kudo, Ann-Lii Cheng, Josep M Llovet, Richard S Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han, None, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet. ,vol. 389, pp. 56- 66 ,(2017) , 10.1016/S0140-6736(16)32453-9
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal, Global cancer statistics, 2012 CA: A Cancer Journal for Clinicians. ,vol. 65, pp. 87- 108 ,(2015) , 10.3322/CAAC.21262
재연 정, Sorafenib in Advanced Hepatocellular Carcinoma ,(2008)
Katherine A. McGlynn, Jessica L. Petrick, W. Thomas London, Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clinics in Liver Disease. ,vol. 19, pp. 223- 238 ,(2015) , 10.1016/J.CLD.2015.01.001
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme De Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F Greten, Peter R Galle, Jean-François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Jordi Bruix, None, Sorafenib in Advanced Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 359, pp. 378- 390 ,(2008) , 10.1056/NEJMOA0708857
Ekaterina Breous, Robert Thimme, Potential of immunotherapy for hepatocellular carcinoma Journal of Hepatology. ,vol. 54, pp. 830- 834 ,(2011) , 10.1016/J.JHEP.2010.10.013
Tobias Flecken, Nathalie Schmidt, Sandra Hild, Emma Gostick, Oliver Drognitz, Robert Zeiser, Peter Schemmer, Helge Bruns, Thomas Eiermann, David A. Price, Hubert E. Blum, Christoph Neumann‐Haefelin, Robert Thimme, Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma Hepatology. ,vol. 59, pp. 1415- 1426 ,(2014) , 10.1002/HEP.26731